Response-guided therapy in patients with genotype 1 hepatitis C virus: Current status and future prospects

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 8, 2014, Pages 1574-1581

  Lawitz, Eric J ^a   Membreno, Fernando E ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Direct acting antiviral; HCV RNA; Protease inhibitors; Response guided therapy

Indexed keywords

ABT 450; BOCEPREVIR; FALDAPREVIR; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROLINE; RECOMBINANT PROTEIN;

ANTIVIRAL THERAPY; DECOMPENSATED LIVER CIRRHOSIS; DRUG POTENCY; HEALTH CARE QUALITY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; KIDNEY FAILURE; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS LOAD; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL (TOPIC); GENETICS; GENOTYPE; HEPACIVIRUS; PHYSIOLOGY; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; RECOMBINANT PROTEINS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

EID: 84904907334     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12632     Document Type: Review

References (65)

1. Swain MG, Lai MY, Shiffman ML etal. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139: 1593-1601.
2. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444.
3. Maruoka D, Imazeki F, Arai M, Kanda T, Fujiwara K, Yokosuka O. Longitudinal changes of the laboratory data of chronic hepatitis C patients with sustained virological response on long-term follow-up. J. Viral Hepat. 2012; 19: e97-104.
4. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
5. Fusco DN, Chung RT. Novel therapies for hepatitis C: insights from the structure of the virus. Annu. Rev. Med. 2012; 63: 373-387.
6. Lee SS, Bain VG, Peltekian K etal. Treasting chronic hepatitis C with pegylated interferon alfa-2a (40KD) and ribavirin in clinical practice. Aliment. Pharmacol. Ther. 2006; 23: 397-408.
7. Manns MP, McHutchison JG, Gordon SC etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
8. Fried MW, Shiffman ML, Reddy KR etal. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002; 347: 975-982.
9. Hadziyannis SJ, Sette H Jr, Morgan TR etal. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 2004; 140: 346-355.
10. McHutchison JG, Lawitz EJ, Shiffman ML etal. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 2009; 361: 580-593.
11. Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002; 36 (Suppl. 1): S145-151.
12. Jensen DM, Morgan TR, Marcellin P etal. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43: 954-960.
13. Zeuzem S, Buti M, Ferenci P etal. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J. Hepatol. 2006; 44: 97-103.
14. Ferenci P, Laferl H, Scherzer TM etal. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135: 451-458.
15. Liu CH, Liu CJ, Lin C etal. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin. Infect. Dis. 2008; 47: 1260-1269.
16. Mangia A, Minerav N, Bacca D etal. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008; 47: 43-50.
17. Yu ML, Dai CY, Huang JF etal. Rapid virological response and treatment duration for chronic hepatitis c genotype 1 patients: a randomized trial. Hepatology 2008; 47: 1884-1893.
18. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J. Hepatol. 2011; 55: 69-75.
19. Moreno C, Deltenre P, Pawlotsky JM, Henrion J, Adler M, Mathurin P. Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis. J. Hepatol. 2010; 52: 25-31.
20. Lam NP, Neumann AU, Gretch DR etal. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26: 226-231.
21. Neumann AU, Lam NP, Dahari H etal. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103-107.
22. Dahari H, Guedj J, Perelson AS, Layden TJ. Hepatitis C viral kinetics in the era of direct acting antiviral agents and IL28B. Curr. Hepat. Rep. 2011; 10: 214-227.
23. Pawlotsky JM. Treatment of chronic hepatitis C: current and future. Curr. Top. Microbiol. Immunol. 2013; 369: 321-342.
24. Pearlman BL. Chronic hepatitis c therapy: changing the rules of duration. Clin. Gastroenterol. Hepatol. 2006; 4: 963-971.
25. Pearlman BL. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. Lancet Infect. Dis. 2012; 12: 717-728.
26. Poordad F, McCone J Jr, Bacon BR etal. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1195-1206.
27. Jacobson IM, McHutchison JG, Dusheiko G etal. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011; 364: 2405-2416.
28. Sherman KE, Flamm SL, Afdhal NH etal. Response-guided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med. 2011; 365: 1014-1024.
29. Bacon BR, Gordon SC, Lawitz E etal. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1207-1217.
30. Vierling JM, Davis M, Flamm S etal. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. J. Hepatol. 2014; 60: 748-756.
31. Zeuzem S, Andreone P, Pol S etal. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 2011; 364: 2417-2428.
32. VICTRELIS™ (boceprevir) [prescribing information]. Whitehouse Station, NJ: Merck & Co.; 2013.
33. INCIVEK™ (telaprevir) [prescribing information]. Cambridge, MA: Vertex Pharmaceuticals Incorporated. 2013.
34. Membreno FE, Lawitz EJ. The HCV NS5B nucleoside and non-nucleoside inhibitors. Clin. Liver Dis. 2011; 15: 611-626.
35. Lawitz E, Mangia A, Wyles D etal. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 2013; 368: 1878-1887.
36. Kowdley K, Lawitz E, Poordad F etal. Phase 2b trial of interferon-free therapy for hepatitis c virus genotype 1. N. Engl. J. Med. 2014; 370: 222-232.
37. Poordad F, Lawitz E, Kowdley KV etal. Exploratory study of oral combination antiviral therapy for hepatitis C. N. Engl. J. Med. 2013; 368: 45-53.
38. Tanwar S, Trembling PM, Dusheiko GM etal. TMC435 for the treatment of chronic hepatitis C. Expert Opin. Investig. Drugs 2012; 21: 1193-1209.
39. Jacobson I, Dore GJ, Foster GR etal. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-1, a phase III trial. J. Hepatol. 2013; 58: S567-577.
40. Manns M, Marcellin P, Poordad FF etal. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-2, a phase III trial. J. Hepatol. 2013; 58: S567-577.
41. Lawitz E, Forns X, Zeuzem S etal. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: results from PROMISE, a phase III trial. Gastroenterology 2013; 77: S151.
42. Manns M, Ressink H, Berg T etal. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial. Antivir. Ther. 2011; 16: 1021-1033.
43. Zeuzem S, Berg T, Gane E etal. Simeprevir increases R=rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014; 146: 430-441.
44. Fried MW, Buti M, Dore GJ etal. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-Naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58: 1918-1929.
45. White PW, Llinas-Brunet M, Amad M etal. Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob. Agents Chemother. 2010; 54: 4611-4618.
46. Manns MP, Bourliere M, Benhamou Y etal. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J. Hepatol. 2011; 54: 1114-1122.
47. Ferenci P, Asselah T, Foster GR etal. Faldaprevir plus pegylated interferon alfa-2a and ribavirin in chronic HCV genotype-1 treatment-naïve patients: final results from STARTVerso1, a randomised, double-blind, placebo-controlled phase III trial. J. Hepatol. 2013; 58: S567-577.
48. Sulkowski MS, Asselah T, Lalezari J etal. Faldaprevir combined with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype-1 HCV: SILEN-C1 trial. Hepatology 2013; 57: 2143-2154.
49. Sulkowski MS, Bourliere M, Bronowicki JP etal. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic HCV genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology 2013; 57: 2155-2163.
50. Jacobson IM, Asselah T, Ferenci P etal. STARTVerso 3: a randomized, double-blind, placebo-controlled phase III trial of faldaprevir in combination with pegylated interferon á-2a and ribavirin in treatment-experienced patients with chronic HCV genotype-1 infection. Hepatology 2013; 58 (Suppl. 1): 742A.
51. Lam AM, Murakami E, Espiritu C etal. PSI-7851, a pronucleotide of beta-D-2′-deoxy-2′-fluoro-2′-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob. Agents Chemother. 2010; 24: 3187-3196.
52. Kowdley KV, Lawitz E, Crespo I etal. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381: 2100-2107.
53. Lawitz E, Lalezari JP, Hassanein T etal. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect. Dis. 2013; 13: 401-408.
54. Membreno FE, Lawitz EJ. Non-interferon therapies for hepatitis C. Curr. Hepat. Rep. 2012; 13: 401-408.
55. Pawlotsky JM. Treatment of hepatitis C: how will we use viral kinetics, response-guided therapy? Curr. Gastroenterol. Rep. 2013; 15: 309-314.
56. Gane EJ, Roberts SK, Stedman CA etal. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376: 1467-1475.
57. Lok AS, Gardiner DF, Lawitz E etal. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 2012; 366: 216-224.
58. Sulkowski MS, Gardiner DF, Rodrigues-Torres M etal. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N. Engl. J. Med. 2014; 370: 211-221.
59. Lawitz E, Poordad FF, Pang PS etal. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014; 383: 515-523.
60. Gane EJ, Stedman CA, Hyland RH etal. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 2013; 368: 34-44.
61. Gane EJ, Stedman CA, Hyland RH etal. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 2014; 146: 736-743.
62. Jacobson IM, Ghalib R, Rodriguez-Torres M etal. SVR results of a once-daily regimen of simeprevir (SMV, TMC435) plus sofosbuvir (SOF, GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: The COSMOS study. The American Association for the Study of Liver Diseases 64th Annual Meeting 2013, Washington, DC, Nov 1-5, 2013.
63. Infectious Diseases Society of America/American Association for the Study of Liver Diseases. Recommendations for testing, managing, and treating hepatitis C. Cited 3 Mar 2014. Available from: http://www.hcvguidelines.org/
64. Lawitz E, Poordad F, Kowdley KV etal. A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. J. Hepatol. 2013; 59: 18-23.
65. Lawitz E, Hezode C, Varunok P etal. Interferon- and ribavirin free regimen of ABT-450/r + ABT-267 in HCV genotype 1b-infected treatment-naive patients and prior null responders. Hepatology 2013; 58 (Suppl. 4): 244A. [Abstract 75].